# Shengfang (Shanghai) Pharmaceutical Research and Development Co.

Startup profile on Capital Atlas: https://capitalatlas.ai/startups/shengfang-shanghai-pharmaceutical-research-and-development-c

- Industry: Healthcare
- Headquarters: Shanghai, China
- Website: www.elixir-research.com
- Total disclosed funding: $52M
- Latest round: Series A (Apr 22, 2022)
- Investors on record: 3

## About

Established in 2019 and based in Shanghai, China, Shengfang (Shanghai) Pharmaceutical Research and Development Co., Ltd. is a healthcare company that focuses on providing clinical CRO research solutions. The company is headquartered in Shanghai and has branches in Beijing, Dalian, Jiaxing, Chengdu, Nanjing and Guangzhou. In April 2022, the company raised USD 52 million in series A funding from new investors.

The company provides clinical study protocol design, medical strategy, regulatory registries, center management, data management, biostatistics and real-world studies, and other clinical research services for customers.

The company plans to use the series A funding for improve the information management level and data value mining capability of the company's R&D, continuously improve the professional service capability of the team, and establish an international delivery team.

## Funding rounds

- Series A, Apr 22, 2022, $52M — Sinovation Ventures, LYFE Capital, Chow Tai Fook Jewellery Company

## Investors

- Sinovation Ventures (https://capitalatlas.ai/funds/sinovation-ventures) — Series A
- LYFE Capital — Series A
- Chow Tai Fook Jewellery Company — Series A